THE ANABOLICPROTOCOL
MedicationsMedium risk

Minoxidil

Also known as: Minoxidil, Rogaine, Regaine, Oral Minoxidil, Minox, Loniten

Works on hair follicles through a mechanism unrelated to DHT — which is exactly why it is the option that still applies under DHT-derived compounds.

Substance family

Hair loss agents

Which one works depends entirely on the cause. 5-alpha-reductase inhibitors block a conversion; receptor blockers block the receptor; minoxidil acts on the growth cycle regardless of androgens.

Effects on

Which outcomes this substance acts on — descriptive, not a recommendation.

Strain profile

Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.

Liver
minimal
Kidneys
low
Blood lipids
minimal
Hematocrit
minimal
Blood pressure
medium
Hormonal axis
minimal

This substance causes

This substance works against

Dosing & protocols by goal

Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.

Topical (approved indication)

Basic

Dose

1 ml of 5% solution or foam

Frequency

2× daily, on a dry scalp

Cycle length

Ongoing — the effect ends when application does

Results take 3–6 months. An initial increase in shedding in the first weeks is expected and is not a sign of failure.

Oral, low dose (off-label)

Advanced

Dose

0.25–2.5 mg / day

Frequency

1× daily

Cycle length

Ongoing, medically supervised

Far below the 10–40 mg used for blood pressure. Increasingly used where topical application is impractical or ineffective, but it is systemic — the side effects are too.

Blood pressure (original indication)

Medical

Dose

10–40 mg / day

Frequency

1× daily

Cycle length

Medically supervised

The original use, reserved for severe hypertension. The hair growth seen at this dose is what led to the topical product.

Supraphysiological doses carry significant health risks and are not legal without a medical indication. This information serves education and harm reduction, not as a usage recommendation. Accompanying blood work and — where relevant — a post-cycle plan (PCT) are essential. See the disclaimer.

Side effect & countermeasure

Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.

Problem

Initial shedding misread as the drug making things worse

Countermeasure

In the first 2–8 weeks, shedding typically increases. This is the expected consequence of follicles being pushed out of the resting phase into a new growth cycle — the old hair is displaced by the new one. Stopping at this point is the most common reason people conclude it does not work, right before it starts to.

Problem

Fluid retention and blood pressure effects with the oral form

Countermeasure

Oral minoxidil is a genuine antihypertensive. Even at low doses it can cause fluid retention, swollen ankles and an elevated heart rate. Relevant for anyone whose blood pressure is already affected by other compounds. Measure at home; this belongs under medical supervision.

Problem

Body hair growth with the oral form

Countermeasure

Hypertrichosis is dose-dependent and affects face, arms and back. It is the most common reason people stop oral minoxidil, and it is not selective — the drug does not distinguish scalp from elsewhere.

Problem

Non-response due to low sulfotransferase

Countermeasure

Minoxidil is a prodrug; the follicle must convert it via sulfotransferase. Activity of that enzyme varies between individuals, which is why a subset simply does not respond topically. Oral dosing bypasses part of the problem.

Problem

Scalp irritation, particularly from propylene glycol

Countermeasure

Irritation, flaking and itching usually come from the solvent rather than the minoxidil. Foam formulations avoid propylene glycol and are considerably better tolerated.

Problem

Effect ends on discontinuation

Countermeasure

Hair maintained by minoxidil is lost within months of stopping, back to where it would have been. This is an indefinite commitment, not a course of treatment.

Overview

Minoxidil began as a blood pressure medication. The hair growth observed as a side effect in patients led to the topical product, which is now one of only two treatments approved for androgenetic alopecia.

For anyone using anabolic compounds, it holds a specific position: it works through a mechanism that has nothing to do with DHT. That makes it the option that still applies where finasteride does not.

Mechanism of Action

Minoxidil opens potassium channels and dilates blood vessels, improving perfusion around the follicle. Beyond that it appears to prolong the growth phase of the hair cycle and shorten the resting phase, and it influences growth factors in the follicle directly. The full mechanism is not completely resolved.

What matters practically is what it does not involve: androgen receptors, DHT, or the conversion between them. Minoxidil does not reduce the androgenic pressure on the follicle — it acts on the follicle's growth behaviour despite that pressure.

This is why it is the answer to a question finasteride cannot address. Under drostanolone, stanozolol or oxandrolone, the follicle is under attack from a DHT derivative that no 5-alpha-reductase inhibitor can touch. Minoxidil does not care about the source of the androgen; it works on the growth cycle regardless.

It is a prodrug — the follicle must activate it via sulfotransferase, and the activity of that enzyme varies between people. This explains topical non-responders, and it is part of why the oral form has gained ground.

Typical Context

Topically, one millilitre of five percent solution or foam twice daily, indefinitely. Results take three to six months.

The single most important thing to know before starting: shedding increases in the first two to eight weeks. This is expected. Follicles are being pushed out of their resting phase into a new growth cycle, and the old hair falls out to make room for the new one. It looks like the treatment is accelerating the problem, and it is the point at which most people quit — immediately before the phase where it starts working.

Low-dose oral minoxidil has become considerably more common, at a fraction of the blood pressure dose. It bypasses the absorption and sulfotransferase problems and is more convenient than twice-daily application. The trade-off is that it is systemic: fluid retention, elevated heart rate and body hair growth are all dose-dependent and all real. For anyone already running compounds that raise blood pressure, adding an antihypertensive with fluid retention as a side effect is a combination that belongs with a doctor.

Side Effects & Risks

  • Initial shedding in the first weeks
  • Scalp irritation, flaking, itching — mostly from propylene glycol in solutions
  • Oral form: fluid retention, swollen ankles, elevated heart rate
  • Oral form: body and facial hair growth (hypertrichosis)
  • Oral form: blood pressure effects
  • Unwanted hair growth on the face from topical runoff
  • Effect ends completely on discontinuation

Blood Work & Monitoring

  • Blood pressure and resting heart rate — for the oral form, measured at home
  • Kidney values (creatinine, eGFR) — relevant with oral use
  • Electrolytes — fluid retention can shift them

Harm-Reduction Notes

  • The initial shedding is expected — stopping then means quitting right before it works
  • It works independently of DHT, which is why it applies under DHT-derived compounds where finasteride does not
  • Foam rather than solution if irritation occurs; the solvent is usually the cause
  • Oral minoxidil is a blood pressure drug — combined with compounds that already raise it, this belongs under medical supervision
  • Apply to a dry scalp and let it dry before lying down, to limit facial runoff
  • It is an indefinite commitment; stopping returns you to baseline within months

Legal status by region

Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.

RegionRegulatory status
United StatesTopical over the counter, oral prescription-onlyTopical 2% and 5% are approved for androgenetic alopecia.
EU / UKTopical pharmacy-only, oral prescription-only
Canada / AustraliaTopical over the counter, oral prescription-only
Most other jurisdictionsTopical widely available
Competitive sportNot prohibited
All content on this page is for information and harm-reduction purposes only. It is not medical advice, not a recommendation to purchase or use, and does not replace consulting a doctor. Legal status and enforcement vary by country and change; verifying the current rules in your own jurisdiction is your responsibility. For adults 18+ only. See the full disclaimer.